Journal of the Society for Integrative Oncology最新文献

{"title":"Comparison of two quality of life instruments for cancer patients: the Ferrans and Powers Quality of Life Index and the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire C30.","authors":"Digant Gupta,&nbsp;James F Grutsch,&nbsp;Christopher G Lis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Health-related quality of life (QoL) in cancer patients cannot be adequately captured with a single instrument. We compared the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and the Ferrans and Powers Quality of Life Index (QLI). We hypothesized that there would be little overlap among their subscales. Baseline QoL data were collected from a consecutive series of 954 cancer patients treated at our center. Data from the two questionnaires were analyzed on a subscale basis using correlation analysis and the Bland-Altman method. The mean and standard deviations of the difference in QoL subscale scores were used to construct 95% limits of agreement among the subscales. Five hundred seventy-nine were females and 375 were males, with a median age of 52 years. There were poor to modest correlations and poor agreement among the subscales of the two instruments. For QLQ-C30 physical and QLI health, the correlation and limits of agreement were 0.6 and -22.2 to 59.8. For QLQ-C30 role and QLI health, the correlation and limits of agreement were 0.6 and -47.3 to 61.5. For QLQ-C30 social and QLI social, the correlation and limits of agreement were 0.2 and -78.2 to 50.2. Consequently, these instruments measure unrelated aspects of QoL and can give different conclusions.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 1","pages":"13-8"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27288717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient satisfaction with quality of life as a prognostic indicator in ovarian cancer patients treated in an integrative treatment setting.","authors":"Digant Gupta,&nbsp;James F Grutsch,&nbsp;Christopher G Lis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extensive data show that quality of life (QoL) tools measuring the activities of daily life provide prognostic information in cancer. Ferrans and Powers Quality of Life Index (QLI) is an instrument measuring patients' satisfaction with their life. This study evaluated the association between QLI and survival in ovarian cancer. We examined a consecutive case series of 90 patients with histologically confirmed stage I-IV ovarian cancer treated at Cancer Treatment Centers of America. QLI measures overall QoL and QoL in four major subscales: Health and Physical, Social and Economic, Psychological and Spiritual, and Family. The Kaplan-Meier method was used to calculate survival. Multivariate Cox regression analyses were then performed to evaluate the joint prognostic significance of QoL and clinical factors. The Health and Physical subscale was marginally statistically significant (p = .08) after controlling for stage at diagnosis, prior treatment history, and other QLI subscales. Our study has demonstrated no statistically significant prognostic association of patient satisfaction with QoL, as measured by the QLI, with survival in ovarian cancer.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 3","pages":"98-104"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27904841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic introduction to research: how not to do research.","authors":"Andrew J Vickers","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this didactic article, I review some prevalent \"myths\" about clinical research: anyone can do research; you can learn how to do research from a book or journal articles; all you need to do statistics is the right software (although Excel will also do); you can do good-quality research at your kitchen sink; and what is important is that you did your best. These myths appear to be particularly prevalent in the complementary and alternative medicine communities. They are based on a clear double standard: most clinicians would express shock and horror at the very thought that someone without appropriate clinical training and qualifications might treat a patient; meanwhile, many clinicians do research with no research qualifications whatsoever. But clinical research can guide clinical decisions that affect the health and well-being of millions of people: it is therefore arguable that poorly conducted research is potentially far more harmful than poor medical practice. As such, it is doubly important that clinical research is conducted by those with appropriate training, statistical help, and institutional support.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 2","pages":"82-5"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590769/pdf/nihms79490.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27491789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune defects in breast cancer patients after radiotherapy.","authors":"Leanna J Standish, Carolyn Torkelson, Frank A Hamill, Daesong Yim, Alicia Hill-Force, Annette Fitzpatrick, Monica Olsen, Sandi Schildt, Erin Sweet, Cynthia A Wenner, Mark R Martzen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The purpose of this study was to evaluate the immune status of women with stage I-III breast cancer after receiving external beam radiotherapy (RT). Fourteen stage I-III, estrogen or progesterone receptor-positive or-negative (FER/PR +-), postsurgical breast cancer patients undergoing a standard course of chemotherapy and radiation were studied. Complete blood counts (CBC) with differential, phagocytic activity, natural killer (NK) cell functional activity, and tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma cytokine activity were measured immediately before and for the six weeks following the completion of radiation therapy. Fatigue levels after completion of RT were measured using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Nonparametric statistical methods (Wilcoxon rank and Spearman correlations) were used to analyze the data. Compared with postchemotherapy, following the completion of RT, these breast cancer patients showed lymphopenia, low functional activity of natural killer lymphocytes, decreased monocyte phagocytic activity, and decreased TNF-alpha production but no neutropenia, no anemia, and no change in interferon-gamma production. Lymphocyte count did not return to normal by the end of the 6-week post-RT observation period. The severity of lymphopenia and low natural killer cell activity was related to RT area but not radiation dose. Patients did not report significant fatigue levels for the 6 weeks after completing RT. Significant decreases in the numbers and functions of cells from both the innate and adaptive immune system were detected following a standard course of radiation therapy for the treatment of breast cancer. Immune deficits in lymphocyte populations and TNF-alpha production, should they persist, may have consequences for immune response to residual or recurrent malignancy following completion of conventional treatment. The use of adjunctive immune therapies which target these specific defects may be warranted in the post-treatment period.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 3","pages":"110-21"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845471/pdf/nihms157524.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27904217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer and the immune system.","authors":"Leanna J Standish, Erin S Sweet, Jeffrey Novack, Cynthia A Wenner, Carly Bridge, Ana Nelson, Mark Martzen, Carolyn Torkelson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This article reviews the evidence that the functioning of both the innate and the adaptive immune system plays a role in preventing relapse in women with breast cancer. Lymphocytes, including T cells, T regulatory cells, and natural killer cells, and their cytokine release patterns are implicated in both primary prevention and recurrence of breast cancer. Cancer prognosis may be related to immune system functional status. The hypothesis that the immune system has a causal role in breast cancer etiology is supported by epidemiologic, preclinical, and clinical research. Empirical support for the concept that immune status and immunomodulatory therapy have important roles in comprehensive breast cancer treatment is provided.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 4","pages":"158-68"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restorative yoga for women with ovarian or breast cancer: findings from a pilot study.","authors":"Suzanne C Danhauer,&nbsp;Janet A Tooze,&nbsp;Deborah F Farmer,&nbsp;Cassie R Campbell,&nbsp;Richard P McQuellon,&nbsp;Rolland Barrett,&nbsp;Brigitte E Miller","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Yoga has demonstrated benefit in healthy individuals and those with various health conditions. There are, however, few systematic studies to support the development of yoga interventions for cancer patients. Restorative yoga (RY) is a gentle type of yoga that has been described as \"active relaxation.\" The specific aims of this pilot study were to determine the feasibility of implementing an RY intervention as a supportive therapy for women diagnosed with ovarian or breast cancer and to measure changes in self-reported fatigue, psychological distress and well-being, and quality of life. Fifty-one women with ovarian (n = 37) or breast cancer (n = 14) with a mean age of 58.9 years enrolled in this study; the majority (61%) were actively undergoing cancer treatment at the time of enrollment. All study participants participated in 10 weekly 75-minute RY classes that combined physical postures, breathing, and deep relaxation. Study participants completed questionnaires at baseline, immediately postintervention, and 2 months postintervention. Significant improvements were seen for depression, negative affect, state anxiety, mental health, and overall quality of life. Fatigue decreased between baseline and postintervention follow-up. Health-related quality of life improved between baseline and the 2-month follow-up. Qualitative feedback from participants was predominantly positive; relaxation and shared group experience were two common themes.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 2","pages":"47-58"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27490780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating integrative medicine research: what can we learn from each other?","authors":"Shamini Jain,&nbsp;Paul J Mills","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 2","pages":"45-6"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27490779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imagery intervention for recovering breast cancer patients: clinical trial of safety and efficacy.","authors":"Lyn Freeman,&nbsp;Lorenzo Cohen,&nbsp;Mary Stewart,&nbsp;Rebecca White,&nbsp;Judith Link,&nbsp;J Lynn Palmer,&nbsp;Derek Welton","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In a phase I National Cancer Institute (NCI)-funded clinical trial, 34 breast cancer survivors, six weeks to one year post-treatment, were recruited to participate in a 6-class, 8-week long imagery stress reduction program entitled \"Envision the Rhythms of Life.\" Patients practiced imagery during and between sessions. Outcomes for quality of life and cortisol rhythm were assessed pre- to post-intervention, in two subsets of survivors (intravenous [IV] chemotherapy, or no IV chemotherapy). Thirty survivors completed the 8-week program. Quality of life outcomes demonstrated statistically and clinically significant outcomes for the functional assessment of cancer therapy-general (FACT-G) global index (p<.001), representing improvements in survivor quality of life related to physical, social/family, emotional, and function well-being. Survivors also improved significantly on the breast cancer (p<.001) and spiritual subscales (p = .008.) Brief symptom inventory (BSI) assessment reported significant improvement for the global index (p<.001) which included the categories of depression, somatization and anxiety. At eight weeks, cortisol rhythm, a biochemical indicator of stress and likelihood of cancer recurrence, produced a trend toward improvement for the fifth time point of the day (p = .18). Likert-based stress scales showed highly significant reductions in stress (p<.0001) with subjects practicing imagery the most producing the best scores. Outcomes suggest the imagery program may significantly improve survivor quality of life and reduce stress.</p>","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 2","pages":"67-75"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27490782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trametes versicolor mushroom immune therapy in breast cancer.","authors":"L. Standish, C. A. Wenner, E. Sweet, C. Bridge, A. Nelson, M. Martzen, J. Novack, C. Torkelson","doi":"10.2310/7200.2008.0016","DOIUrl":"https://doi.org/10.2310/7200.2008.0016","url":null,"abstract":"Data from multiple epidemiologic and clinical studies on immune effects of conventional cancer treatment and the clinical benefits of polysaccharide immune therapy suggest that immune function has a role in breast cancer prevention. Immune therapy utilizing the polysaccharide constituents of Trametes versicolor (Tv) as concurrent adjuvant cancer therapy may be warranted as part of a comprehensive cancer treatment and secondary prevention strategy.","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 3 1","pages":"122-8"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2310/7200.2008.0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68604787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune defects in breast cancer patients after radiotherapy.","authors":"L. Standish, C. Torkelson, F. A. Hamill, D. Yim, A. Hill-Force, Annette L. Fitzpatrick, M. Olsen, S. Schildt, E. Sweet, C. A. Wenner, M. Martzen","doi":"10.2310/7200.2008.0018","DOIUrl":"https://doi.org/10.2310/7200.2008.0018","url":null,"abstract":"The purpose of this study was to evaluate the immune status of women with stage I-III breast cancer after receiving external beam radiotherapy (RT). Fourteen stage I-III, estrogen or progesterone receptor-positive or-negative (FER/PR +-), postsurgical breast cancer patients undergoing a standard course of chemotherapy and radiation were studied. Complete blood counts (CBC) with differential, phagocytic activity, natural killer (NK) cell functional activity, and tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma cytokine activity were measured immediately before and for the six weeks following the completion of radiation therapy. Fatigue levels after completion of RT were measured using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Nonparametric statistical methods (Wilcoxon rank and Spearman correlations) were used to analyze the data. Compared with postchemotherapy, following the completion of RT, these breast cancer patients showed lymphopenia, low functional activity of natural killer lymphocytes, decreased monocyte phagocytic activity, and decreased TNF-alpha production but no neutropenia, no anemia, and no change in interferon-gamma production. Lymphocyte count did not return to normal by the end of the 6-week post-RT observation period. The severity of lymphopenia and low natural killer cell activity was related to RT area but not radiation dose. Patients did not report significant fatigue levels for the 6 weeks after completing RT. Significant decreases in the numbers and functions of cells from both the innate and adaptive immune system were detected following a standard course of radiation therapy for the treatment of breast cancer. Immune deficits in lymphocyte populations and TNF-alpha production, should they persist, may have consequences for immune response to residual or recurrent malignancy following completion of conventional treatment. The use of adjunctive immune therapies which target these specific defects may be warranted in the post-treatment period.","PeriodicalId":87409,"journal":{"name":"Journal of the Society for Integrative Oncology","volume":"6 3 1","pages":"110-21"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2310/7200.2008.0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68604794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}